884 results on '"Woermann B"'
Search Results
302. Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia
303. Immunomodulation and Therapeutic Effects of a Monotherapy with Interleukin-2 as an Induction Therapy in Patients with Poor-Prognosis Acute Myeloid Leukemia
304. The Influence of Dysplastic Hematopoiesis on the Outcome in Patients with de Novo AML
305. Blood Stem Cell Transplantation in Acute Myeloid Leukemia
306. Stratification of Postremission Therapy in Adult Acute Myeloid Leukemia According to the Karyotype — Preliminary Results of the Multicenter Treatment Trial AML HD93
307. Abundance of Auer Bodies and Bilobed Nuclei of Leukemic Cells may be Related to Longer Disease Free Survival of Patients with Acute Promyelocytic Leukemia (M3)
308. Trial to Extract Prognostic Factors Prior to the Start of Induction Chemotherapy for Adult AML
309. The Effect of ATRA (Roche) on Clinical and Laboratory Parameters in 36 APL Patients — Polish Multicenter Retrospective Analysis
310. Stem Cell Transplants in Acute Myeloid Leukaemia (AML)
311. Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up
312. Continuous Infusion of Mitoxantrone Combined with High Dose Cytarabine (c-HAM) in de Novo AML
313. Improved Results of AML Treatment in Adults during a 12-Year Period. A Population-Based Study
314. Oral Idarubicin in the Treatment of AML
315. Acute Myeloid Leukemia in Patients Aged Over 75 Years: Clinico-Hematological Characteristics and Treatment Results
316. Oral Chemotherapy for Acute Myeloid Leukaemia
317. Flow Cytometry of Leukocyte Alkaline Phosphatase in Human Hematopoietic Cells
318. Expression of Differentiation Antigens on Blast Cells of Acute Myelogenous Leukemia (AML, M0–M6)
319. Recent Studies in AML, RAEB-t, and RAEB at M.D. Anderson Hospital
320. FLAG-Ida, an Effective Regimen for High Risk AML
321. Risk Factors for Survival in Children with Refractory AML Treated According to AML Relapse Strategies
322. Autologous Bone Marrow Transplantation in First Complete Remission as Intensification Therapy in Children with High Risk AML — Results of the Pediatric Cooperative AML Trial 1987–1992 in East Germany
323. Mutations of Mitochondrial DNA as an Early Event in the Pathogenesis of Myelodysplastic Syndromes
324. The Premyelodysplastic State and the Secondary Hematologic Disorders
325. Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamenthasone Produces Encouraging Results in Myelodysplastic Syndromes
326. Acute Erythroblastic Leukemia is a Rare, but Distinct Subtytpe of Acute Myeloid Leukemia
327. Anomalistic Signaling as a Possible Biochemical Explanation for Discordant Maturation in Chronic Myelogenous Leukemia (CML)
328. Expression of Tie Receptor Tyrosine Kinase in Leukemia Cell Lines
329. New Isoforms of the ZFM1 Gene: a Growing Family of Signal Transduction and Activator of RNA (STAR) Proteins
330. Alterations in DNA Repair: Implications for Leukemia Cell Biology
331. Transformation of Myeloid Cells by the BCR/ABL Oncogene
332. Structural Properties of the Cell Membrane of Apoptosis-Induced Cells and Leucemic Blast Cells Studied by Electrospinresonance-Spectroscopy
333. CD95-Mediated Apoptosis in Acute Myeloid Leukemia (AML): Dependence on Maturational Stage and Growth Characteristics in Vitro
334. CD95(Fas/APO-1) Antigen Expression on the Cells of Myelodysplastic Syndromes, Acute Myelogenous Leukemia, and Chronic Myelogenous Leukemia Patients
335. Simultaneous Detection of Leukemia Blast Cells on PB/BM — Smears Combining May-Gruenwald Giemsa- and APAAP Staining
336. Physiological Events during Ara-C Toxicity Mapped Using Multiparametric Flow Cytometry
337. Evaluation Of NOD-SCID-Mice for a Human B-Cell Precursor ALL Xenograft Model
338. Acute Leukemias with Hybrid Features in Children and Adolescents from the Kiev Region (Ukraine)
339. Immunophenotypical Subtype of Childhood T-All with Favourable Outcome in the COALL 1985–1992 Study Group
340. Flow Cytometric Analysis of Immature Cell Populations in B-Cell Precursor ALL
341. Phase II Trial of Idarubicin, Fludarabine, Cytosine Arabinoside and Filgrastim (G-CSF) for Treatment of Refractory, Relapsed, and Secondary Acute Myeloid Leukemia
342. Current Status of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in the Management of Acute Lymphoblastic Leukemia
343. Molecular Biological Detection of Minimal Residual Disease in Acute Myeloid Leukemia
344. Preclinical Evaluation of Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin 3 Fusion Protein (PIXY 321) in Acute Myeloid Leukemic Cells
345. Initial Trial of PIXY 321 Following Autologous Bone Marrow Transplantation
346. Granulocyte-Macrophage Colony-Stimulating Factor-Based Priming Concepts in Acute Myeloid Leukemia
347. Cancer and Leukemia Group B Studies with Hematopoietic Growth Factors in Patients with Acute Myeloid Leukemia
348. Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia
349. Mechanisms of Regulated Drug Sensitivity
350. Lymphoid Antigen Expression in Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.